144 related articles for article (PubMed ID: 32604198)
21. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications.
Parsons LHP; Pedersen R; Richardson DL; Kho KA
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():108-112. PubMed ID: 29518640
[TBL] [Abstract][Full Text] [Related]
22. Laparoscopic supracervical hysterectomy with transcervical morcellation and sacrocervicopexy: initial experience with a novel surgical approach to uterovaginal prolapse.
Rosenblatt PL; Apostolis CA; Hacker MR; DiSciullo A
J Minim Invasive Gynecol; 2012; 19(6):749-55. PubMed ID: 23084680
[TBL] [Abstract][Full Text] [Related]
23. Morcellation of occult uterine malignancies: an Australian single institution retrospective study.
Tan A; Salfinger S; Tan J; Cohen P
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):503-6. PubMed ID: 26314239
[TBL] [Abstract][Full Text] [Related]
24. Uterine-preserving surgeries for the repair of pelvic organ prolapse: a systematic review with meta-analysis and clinical practice guidelines.
Meriwether KV; Balk EM; Antosh DD; Olivera CK; Kim-Fine S; Murphy M; Grimes CL; Sleemi A; Singh R; Dieter AA; Crisp CC; Rahn DD
Int Urogynecol J; 2019 Apr; 30(4):505-522. PubMed ID: 30741318
[TBL] [Abstract][Full Text] [Related]
25. Occult Leiomyosarcomas in a Canadian Province: A Retrospective Cohort Study.
Wu CQ; Woo LY; Giede KC; Thiel J; Karreman E; Rattray DD
J Obstet Gynaecol Can; 2019 Jan; 41(1):46-51. PubMed ID: 30341020
[TBL] [Abstract][Full Text] [Related]
26. Factors affecting women's decision between uterine-preserving versus hysterectomy-based surgery for pelvic organ prolapse.
Ramage K; Ducey A; Scime NV; Knox E; Brennand EA
Womens Health (Lond); 2023; 19():17455057231181015. PubMed ID: 37387264
[TBL] [Abstract][Full Text] [Related]
27. Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy.
Xu X; Lin H; Wright JD; Gross CP; Boscoe FP; Hutchison LM; Schwartz PE; Desai VB
J Clin Oncol; 2019 Dec; 37(35):3412-3424. PubMed ID: 31518176
[TBL] [Abstract][Full Text] [Related]
28. Pelvic organ prolapse surgery after native tissue vault suspension at hysterectomy-A prospective cohort study.
Bonde L; Østergaard L; Fosbøl EL; Møller LA; Ottesen B; Gislason GH; Gimbel H
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():144-150. PubMed ID: 31284088
[TBL] [Abstract][Full Text] [Related]
29. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
30. Pelvic organ prolapse after laparoscopic hysterectomy compared with vaginal hysterectomy: the POP-UP study.
Vermeulen CKM; Veen J; Adang C; van Leijsen SAL; Coolen AWM; Bongers MY
Int Urogynecol J; 2021 Apr; 32(4):841-850. PubMed ID: 33170314
[TBL] [Abstract][Full Text] [Related]
31. Role of concurrent vaginal hysterectomy in the outcomes of mesh-based vaginal pelvic organ prolapse surgery.
Forde JC; Chughtai B; Anger JT; Mao J; Sedrakyan A
Int Urogynecol J; 2017 Aug; 28(8):1183-1195. PubMed ID: 28091710
[TBL] [Abstract][Full Text] [Related]
32. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.
Multinu F; Casarin J; Tortorella L; Huang Y; Weaver A; Angioni S; Melis GB; Mariani A; Stewart EA; Laughlin-Tommaso SK
Am J Obstet Gynecol; 2019 Feb; 220(2):179.e1-179.e10. PubMed ID: 30447212
[TBL] [Abstract][Full Text] [Related]
33. Unanticipated Uterine and Cervical Malignancy in Women Undergoing Hysterectomy for Uterovaginal Prolapse.
Andiman SE; Bui AH; Hardart A; Xu X
Female Pelvic Med Reconstr Surg; 2021 Jun; 27(6):e549-e554. PubMed ID: 33208657
[TBL] [Abstract][Full Text] [Related]
34. Abdominal and vaginal pelvic support with concomitant hysterectomy for uterovaginal pelvic prolapse: a comparative systematic review and meta-analysis.
Alfahmy A; Mahran A; Conroy B; Brewka RR; Ibrahim M; Sheyn D; El-Nashar SA; Hijaz A
Int Urogynecol J; 2021 Aug; 32(8):2021-2031. PubMed ID: 34050771
[TBL] [Abstract][Full Text] [Related]
35. Protocol for a prospective multisite cohort study investigating hysterectomy versus uterine preservation for pelvic organ prolapse surgery: the HUPPS study.
Scime NV; Ramage K; Brennand EA;
BMJ Open; 2021 Oct; 11(10):e053679. PubMed ID: 34607873
[TBL] [Abstract][Full Text] [Related]
36. Assessing the risk of laparoscopic morcellation of occult uterine sarcomas during hysterectomy and myomectomy: Literature review and the ISGE recommendations.
Sizzi O; Manganaro L; Rossetti A; Saldari M; Florio G; Loddo A; Zurawin R; van Herendael B; Djokovic D
Eur J Obstet Gynecol Reprod Biol; 2018 Jan; 220():30-38. PubMed ID: 29149644
[TBL] [Abstract][Full Text] [Related]
37. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of surgical procedures to prevent post-hysterectomy pelvic organ prolapse: a systematic review of the literature.
Carlin GL; Bodner-Adler B; Husslein H; Ritter M; Umek W
Int Urogynecol J; 2021 Apr; 32(4):775-783. PubMed ID: 33150453
[TBL] [Abstract][Full Text] [Related]
39. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
40. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study.
Skorstad M; Kent A; Lieng M
Acta Obstet Gynecol Scand; 2016 Sep; 95(9):984-90. PubMed ID: 27223683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
